Drug survival rates and reasons for drug discontinuation in psoriasis

2016 ◽  
Vol 14 (11) ◽  
pp. 1089-1099 ◽  
Author(s):  
Tobias Arnold ◽  
Marthe-Lisa Schaarschmidt ◽  
Raphael Herr ◽  
Joachim E. Fischer ◽  
Sergij Goerdt ◽  
...  
Keyword(s):  
Survival Rates ◽  
Drug Discontinuation ◽  
Drug Survival

Drug survival rates and reasons for drug discontinuation in patients with atopic dermatitis: a retrospective study of adult outpatients

2021 ◽  
Vol 31 (2) ◽  
pp. 233-238
Author(s):  
Jehane Pino Lopez ◽  
Christian Kromer ◽  
Raphael Herr ◽  
Astrid Schmieder ◽  
Christiane Bayerl ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Retrospective Study ◽  
Survival Rates ◽  
Drug Discontinuation ◽  
Drug Survival

scholarly journals Biologic Drug Survival in Psoriasis: A Systematic Review & Comparative Meta-Analysis

2020 ◽  
Author(s):  
Ahmed I Mourad ◽  
Robert Gniadecki
Keyword(s):  
Real World ◽  
Survival Data ◽  
Clinical Decision Making ◽  
Meta Analysis ◽  
Survival Rates ◽  
Clinical Decision ◽  
Drug Discontinuation ◽  
Large Variability ◽  
Drug Survival ◽  
Biologic Drug

Background: Drug survival studies have been utilized to evaluate the real-world effectiveness of biologics used in psoriasis. However, the increasing volume of drug survival data suffers from large variability due to regional differences in drug availability, patient selection and biologic reimbursement. Objectives: To conduct a meta-analysis of biologic drug survival to determine comparative effectiveness of the biologics in a real-world setting. Methods: Studies reporting drug survival for biologic therapy in psoriasis were identified by a systematic literature search. Hazard ratio data for drug discontinuation were estimated directly from published Kaplan-Meier estimator curves at year 1, 2 and 5 of treatment and compared pairwise for the following biologics: ustekinumab, adalimumab, etanercept, infliximab, secukinumab and ixekizumab. This pooled hazard ratios were used to estimate 2- and 5- year overall drug survival rates. Results: Ustekinumab had the longest persistence at 2 years and 5 years among all biologics included in this meta-analysis. Adalimumab was superior to etanercept and infliximab at 5 years. Pooled 5-year drug survival rates for adalimumab, etanercept, and infliximab were 46.3%, 35.9% and 34.7%, respectively. 2- and 5-year data were not available for anti-IL-17 drugs, but at 1-year ustekinumab outperformed secukinumab, the latter being equal to anti-TNFs. Conclusions: Ustekinumab is characterized by longer drug survival than TNF inhibitors and IL-17 inhibitors. Estimated pooled 2- and 5- year drug survival rates may serve as a useful tool for patient communication and clinical decision-making.

scholarly journals Biologic Drug Survival in Psoriasis: A Systematic Review & Comparative Meta-Analysis

2021 ◽  
Vol 7 ◽  
Author(s):  
Ahmed I. Mourad ◽  
Robert Gniadecki
Keyword(s):  
Real World ◽  
Survival Data ◽  
Clinical Decision Making ◽  
Meta Analysis ◽  
Survival Rates ◽  
Clinical Decision ◽  
Drug Discontinuation ◽  
Large Variability ◽  
Drug Survival ◽  
Biologic Drug

Drug survival studies have been utilized to evaluate the real-world effectiveness of biologics used in psoriasis. However, the increasing volume of drug survival data suffers from large variability due to regional differences in drug availability, patient selection and biologic reimbursement. The objective of this study was to conduct a meta-analysis of biologic drug survival to determine comparative effectiveness of the biologics in a real-world setting. Studies reporting drug survival for biologic therapy in psoriasis were identified by a systematic literature search. Hazard ratio data for drug discontinuation were estimated directly from published Kaplan-Meier estimator curves at year 1, 2, and 5 of treatment and compared pairwise for the following biologics: ustekinumab, adalimumab, etanercept, infliximab, secukinumab, and ixekizumab. This pooled hazard ratios were used to estimate 2- and 5-year overall drug survival rates. Ustekinumab had the longest persistence at 2 and 5 years among all biologics included in this meta-analysis. Adalimumab was superior to etanercept and infliximab at 5 years. Pooled 5-year drug survival rates for adalimumab, etanercept, and infliximab were 46.3, 35.9, and 34.7%, respectively. Two- and five-year data were not available for anti-IL-17 drugs, but at 1-year ustekinumab outperformed secukinumab, the latter being equal to anti-TNFs. In conclusion, ustekinumab is characterized by longer drug survival than TNF inhibitors and IL-17 inhibitors. Estimated pooled 2- and 5-year drug survival rates may serve as a useful tool for patient communication and clinical decision-making.

scholarly journals Long-Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A Systematic Review of European National Drug Registers

2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
Anamika Arora ◽  
Anadi Mahajan ◽  
Dean Spurden ◽  
Helen Boyd ◽  
Duncan Porter
Keyword(s):  
Systematic Review ◽  
English Language ◽  
Survival Rates ◽  
Pooled Analysis ◽  
Tnf Inhibitors ◽  
Drug Discontinuation ◽  
Tnf Inhibitor ◽  
Drug Survival ◽  
Lower Drug ◽  
Underlying Mechanisms

Objective. The present systematic review of RA registry data was undertaken to analyse the time on treatment of licensed TNF inhibitors in patients with RA in Europe.Methods. English language European registry studies comparing TNF inhibitors were searched using MEDLINE, Embase, Cochrane, and WHO: ICTRP up to 16 April 2012 and proceedings of three selected conferences held between 2010 and 2012. Pooled analysis was performed to determine drug survival rates for each TNF inhibitor.Results. Sixteen studies met the inclusion criteria, of which 11 studies assessed biologic-naive patients and five studies included a mixed population of biologic-naive and biologic pretreated patients. The overall effectiveness of TNF inhibitors diminished with time, leading to decreased drug survival rates. Pooled drug survival rates after 60 months follow-up were 37% (infliximab), 48% (adalimumab), and 52% (etanercept). Further, in an observational study, when TNF inhibitors were used in combination with methotrexate, a longer drug survival was observed compared to TNF inhibitors alone.Conclusion. The findings of this systematic review indicated numerically lower drug discontinuation rates with etanercept than adalimumab, whereas infliximab had the highest rate. Further research is needed to understand the underlying mechanisms of treatment discontinuation with TNF inhibitors.

Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis

2016 ◽  
Vol 51 (5) ◽  
pp. 388-393 ◽  
Author(s):  
María Henar García-Lagunar ◽  
María Rocío Gutiérrez-Cívicos ◽  
María Sergia García-Simón ◽  
Pablo Conesa-Zamora ◽  
Enrique Jimenez-Santos ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Ankylosing Spondylitis ◽  
Adverse Effects ◽  
Dosage Regimen ◽  
Survival Rates ◽  
Drug Survival ◽  
Kaplan Meier ◽  
Tnfα Inhibitors ◽  
Treatment Objective ◽  
Factor Α

Background: The introduction of anti–tumor necrosis factor α (anti-TNFα) drugs has improved the clinical outcomes in rheumatoid arthritis (RA) and ankylosing spondylitis (AS). However, these drugs may cause adverse effects that motivate a change in or discontinuation of the treatment. Objective: To evaluate the causes of discontinuation or changes in the dosage regimen in a cohort of patients with RA and AS treated with infliximab, adalimumab, etanercept, and golimumab under clinical practice conditions. Methods: This was a retrospective observational study that included patients with RA or AS treated with anti-TNFα drugs between 2008 and 2013. Changes in the dosage regimen, reasons for treatment discontinuation, and adverse effects were recorded and analyzed. Time to discontinuation was estimated using Kaplan-Meier survival analysis. Results: A total of 123 patients with RA and 93 patients with AS were treated with anti-TNFα therapy. During the study, 55.3% of RA patients and 41.7% of AS patients had stopped the treatment. The most frequent changes were modifications in the dosing, and the most frequent adverse effects were reactions after the infusion or injection (53.8% and 66.7% in RA and AS, respectively). Drug survival of etanercept in RA (67.9%) is greater than for adalimumab and infliximab, whereas drug survival of infliximab in AS (70.0%) is greater than for etanercept and adalimumab at 5 years, although there were no significant differences ( P = 0.098 in RA and 0.194 in AS). Conclusions: The main cause of discontinuation of anti-TNFα is therapeutic failure in both diseases. Etanercept and infliximab have the best survival rates in RA and AS, respectively.

scholarly journals Drug survival and reasons for drug discontinuation in palmoplantar pustulosis: a retrospective multicenter study

2019 ◽  
Vol 17 (5) ◽  
pp. 503-516 ◽  
Author(s):  
Christian Kromer ◽  
Dagmar Wilsmann‐Theis ◽  
Sascha Gerdes ◽  
Sandra Philipp ◽  
Marthe‐Lisa Schaarschmidt ◽  
...  
Keyword(s):  
Multicenter Study ◽  
Drug Discontinuation ◽  
Palmoplantar Pustulosis ◽  
Drug Survival ◽  
Retrospective Multicenter Study

Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris

2011 ◽  
Vol 164 (5) ◽  
pp. 1091-1096 ◽  
Author(s):  
R. Gniadecki ◽  
K. Kragballe ◽  
T.N. Dam ◽  
L. Skov
Keyword(s):  
Psoriasis Vulgaris ◽  
Survival Rates ◽  
Drug Survival
Sign in / Sign up

Export Citation Format

Share Document